SCHEMBL6355073

SCHEMBL6355073

O=C(NCc1cc(Cl)ccc1Cl)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
HPGD P15428 5/20 0.54
ALDH1A1 P00352 4/20 0.54
MAPK8 P45983 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CYP1A2 P05177 1/20 0.51
KDM4E B2RXH2 2/20 0.51
RCE1 Q9Y256 1/20 0.51
LMNA P02545 2/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357804 0.89 ALDH1A1 (0.62) MEN1KMT2AHPGDALDH1A1CYP1A2
SCHEMBL6357168 0.88 P2RX7 (0.53) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL6357794 0.88 TSHR (0.64) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL3461761 0.83 SMN1; SMN2 (0.60) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL6360998 0.80 KMT2A (0.60) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL6358889 0.80 ALDH1A1 (0.65) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL5645008 0.80 HPGD (0.57) L3MBTL1HPGDALDH1A1CYP1A2LMNA
SCHEMBL6362508 0.78 HPGD (0.50) MEN1KMT2AL3MBTL1HPGDALDH1A1
SCHEMBL3557506 0.77 P2RX7 (0.53) MEN1KMT2AALDH1A1TDP1LMNA
SCHEMBL5645103 0.77 HPGD (0.62) KMT2AL3MBTL1HPGDALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 MEN1 3860/4885KMT2A 1711/4885L3MBTL1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.